4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Shanghai Henlius Biotech, Inc. (2696) operates in the Biotechnology industry and is headquartered in Shanghai, China with about 4,082 employees. Its market capitalization is roughly HK$32 billion. In the fiscal year ended 2025-12-31, 2696 reported CNY 6.7B in revenue and CNY 827M in net income.
Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases.
Interactive charts & full statements → Open the 2696 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | CNY 6.7B | CNY 5.7B | CNY 5.4B | CNY 3.2B |
| Gross Profit | CNY 5.0B | CNY 4.2B | CNY 3.9B | CNY 2.4B |
| Operating Income (EBIT) | CNY 928M | CNY 939M | CNY 722M | (CNY 359M) |
| Net Income | CNY 827M | CNY 820M | CNY 546M | (CNY 695M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 12.4B | CNY 10.6B | CNY 9.9B | CNY 8.9B | — |
| Total Liabilities | CNY 8.4B | CNY 7.6B | CNY 7.7B | CNY 7.3B | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2696 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms